NEW DELHI, March 4, 2026 — Osstem Implant, the world’s largest dental implant company by sales volume, is stepping up its global expansion as it aims to become the “Global No. 1 Dental Company,” supported by new production bases and a strengthened quality management system.
The company recently brought its manufacturing facility in Brazil into full operation, joining existing plants in South Korea, the United States and China. The move completes what Osstem calls its “Global 4-Region Manufacturing Belt,” designed to support rising demand for dental implants worldwide.
Osstem said its global annual production capacity now exceeds 22 million implant sets, enabling faster response to growing international demand.
In 2025, the company also expanded its research infrastructure by completing the “Triple Tower,” an R&D complex in Songdo International City, South Korea. At the same time, Osstem strengthened its presence in the Americas through the acquisition of Implacil, Brazil’s third-largest implant company, and by expanding its manufacturing facility in Pennsylvania.
A key driver of the company’s growth strategy is its strict quality control approach. Osstem applies internal standards that exceed international Good Manufacturing Practice (GMP) requirements and targets a defect rate of under 100 parts per million, or fewer than one defective product per 10,000 units.
To maintain quality consistency, the company operates a “six major key process management” system along with a five-stage inspection process covering self-inspection, machining checks, surface inspection, incoming inspection and final shipping inspection.
Osstem also maintains specialized manufacturing environments such as cleanrooms and deionized water facilities, while operating an advanced quality management system designed to respond quickly to customer feedback.
The company has obtained multiple international certifications, including Korea’s KGMP, U.S. FDA approval, Europe’s MDR certification, Japan’s QMS and China’s CFDA authorization, confirming the safety and performance of its dental implant products.
Research and development remain central to Osstem’s long-term strategy. The company invests more than 10% of its annual revenue into R&D and employs about 900 researchers across 15 specialized institutes within the Osstem Central Research Institute. These teams work on areas including implants, dental equipment, materials, orthodontics and digital dentistry.
Through these investments, Osstem aims to develop essential dental treatment technologies in-house and position itself as a “total solution provider” for the dental industry, rather than solely an implant manufacturer.
The company’s technologies have also gained international attention. At AEEDC Dubai 2026, the Middle East’s largest dental exhibition held in January, dentists praised Osstem’s SOI implants and digital solutions for their potential to significantly shorten healing times.
“Our strict quality standards and continued R&D investment are key to our quality-first management philosophy,” an Osstem Implant official said. “With a goal of reaching 3 trillion won in sales by 2028, we aim to fulfill our role as a global dental provider by delivering the highest quality products to clinicians worldwide.”